Solifenacin
As of the edition of 20 October 2026, Solifenacin is a small molecule: marketed, first approved in 2004 (ES); acts on CHRM2 and CHRM3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Small molecule
- Brand name
- Vesicare
- First approved
- 30 July 2004 (ES)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- Astellas; 2 holders in all
- Registered trials
- 105, 7 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Nervous system; Inherited and neonatal; Cancer; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Solifenacin.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 24 | 17 | 2 | 2 |
| Phase 1 | 14 | 14 | 0 | 0 |
| Phase 2 | 7 | 4 | 2 | 0 |
| Phase 3 | 21 | 16 | 2 | 1 |
| Phase 4 | 39 | 28 | 4 | 4 |
| All trials | 105 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Applicant and Lead sponsor of trials | 2003 to now |